PERRIN H. LONG, M.D.; JAMES W. HAVILAND, M.D.
This content is PDF only. Please click on the PDF icon to access.
In 1939 Long and Wood1 reported that the case fatality rate in pneumococcal pneumonia at The Johns Hopkins Hospital had been reduced to 7.2 per cent during the previous year by the therapeutic use of antipneumococcal serum, sulfapyridine, or a combination of these two agents. During the past year we have continued our observations upon the value of chemotherapeutic agents in the treatment of pneumococcal pneumonia in adult patients. Originally, we planned only to continue the use of sulfapyridine, but late in 1939, as a result of the work of McKee et al.2, 3 and of work carried out in
LONG PH, HAVILAND JW. THE PROBLEM OF PNEUMONIA WITH REFERENCE TO CHEMO- AND SERO-THERAPY1. Ann Intern Med. ;14:1042–1049. doi: 10.7326/0003-4819-14-6-1042
Download citation file:
Published: Ann Intern Med. 1940;14(6):1042-1049.
Infectious Disease, Pneumonia, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use